Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
A federal judge ruled that the Trump administration unlawfully removed gender-affirming care from the ACA's essential health benefits, restoring key financial protections for transgender patients. The ruling means insurers can no longer exclude these services from out-of-pocket caps or impose lifetime dollar limits. However, it stops short of requiring all insurers to cover gender-affirming care outright.
A Massachusetts federal judge has vacated a Trump administration policy that stripped gender-affirming care of its "essential health benefit" status under the Affordable Care Act. U.S. District Judge Nathaniel Gorton ruled that HHS unlawfully revised the scope of essential health benefits without submitting a congressionally required actuarial certification report. The decision, celebrated by a coalition of 21 state attorneys general, restores critical financial protections for transgender patients in states that permit such care.
The practical stakes are significant. Under the now-vacated policy, insurers could still voluntarily cover gender-affirming care — but patient spending wouldn't count toward deductibles or out-of-pocket maximums, and the care could be subject to lifetime dollar limits. That meant patients receiving ongoing prescriptions or monitoring could face mounting bills even after hitting their plan's ordinary spending cap, potentially forcing delays or interruptions in care.
Still, the ruling leaves open questions. It doesn't require every insurer to cover gender-affirming care, nor does it clarify how plans should handle claims processed under the old policy. CMS and state regulators will need to issue guidance on next steps.
Key Takeaways:
Why it matters: This ruling has real financial consequences for transgender patients who rely on the ACA marketplace for coverage. Restoring essential health benefit status means more predictable costs and stronger protections — but the legal and regulatory landscape remains unsettled, leaving patients and insurers in a period of uncertainty.
